Medication before and after a spinal cord lesion

Area of Science:

• Pharmacology and Toxicology
• Neurology
• Rehabilitation Medicine

Background:

• Spinal cord lesions (SCL) represent a significant challenge in patient care.
• Understanding the medication needs post-SCL is crucial for effective management.

Purpose of the Study:

• To quantify the impact of spinal cord lesions (SCL) on medication requirements.
• To identify specific medication categories and patient subgroups most affected by SCL.

Main Methods:

• Medication data was collected for 72 patients before SCL and at discharge.
• Changes in medication were analyzed across Anatomical Therapeutic Chemical (ATC) groups.
• Subgroup analyses included injury type, severity (AIS scale), and demographics.

Main Results:

• A significant overall increase in medication use (3.29 times) was observed post-SCL (P<0.001).
• Medication in 'Alimentary tract and metabolism' and 'Nervous system' categories showed consistent increases.
• Patients with more severe injuries (AIS A, B, C) exhibited the highest medication increases compared to AIS D.

Conclusions:

• Spinal cord lesions (SCL) lead to a substantial rise in medication requirements.
• The increase is most pronounced in patients with severe SCL (AIS A, B, C).
• These medication changes may have implications for adverse effects and healthcare economics.